Drug Insight: an overview of current anticoagulation therapy after heart valve replacement
Detlef Hering*, Cornelia Piper and Dieter Horstkotte
Correspondence *Department of Cardiology, Heart Center North Rhine-Westphalia, Ruhr University Bochum, Georgstrasse 11, 32545, Bad Oeynhausen, Germany
Email akohlstaedt@hdz-nrw.de
Patients who receive most types of modern prosthetic heart valve are currently also given long-term, low-intensity anticoagulation therapy to reduce the risk of thromboembolic complications. In this review, the authors discuss the current recommendations for anticoagulation therapy and the data on which these recommendations are based.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$32 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
NEWS AND VIEWS
Thrombi?beware of red cells bearing giftsNature Biotechnology News and Views (01 Aug 2003)
RESEARCH
The effect of oral anticoagulation on clotting during hemodialysisKidney International Original Article
See all 26 matches for Research